Recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Kalaja, V V ^a,b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG RESPONSE; FOLLOW UP; HUMAN; HYPERCALCEMIA; METASTASIS; MONOTHERAPY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 36848999516     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm016     Document Type: Article

References (19)

1. Rosen PP, Groshen S, Saigo PE et al. Pathological prognostic factors in stage I (T1NOMO) and stage II (T1N1MO) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-1251.
2. Stockler M, Wilcken NRC, Ghersi D, Simes RJ. Systemic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26: 151-168.
3. Fossati R, Confalonieri C, Torri V et al, Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving. 31 510 women. J Clin Oncol 1998; 16: 3439-3460.
4. Body J-J. Bisphosphonates in breast cancer and other solid tumors. In Rubens R, Mundy GR (eds): Cancer and the Skeleton. London, UK: Martin Dunitz Ltd. 2000; 231-243.
5. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
6. Klijn JG, Blarney RW, Boccardo F et al. Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormonereleasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353.
7. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 2006; 98: 1285-1291.
8. Bonneterre J, Thürlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
9. Nabholtz A Buzdar A, Pollak M et al. Anastrozole is superior to Tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American Multicenter Randomized Trial. J Clin Oncol 2000; 18: 3758-3767.
10. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
11. Osborne CK, Pippen J, Jones SE at al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
12. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI, 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
13. Seidman AD. Sequential single-agent chemotherapy for metastatic breast cancer: Therapeutic nihilism or realism? J Clin Oncol 2003; 21:577-579.
14. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-1495.
15. Falkson G, Gelman RS, Pandya KJ et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16:1669-1676.
16. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patents with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
17. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
18. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001; 344: 783-779.
19. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N EngI J Med 2000; 342: 1069-1076.